摘要
目的:补充完善佤族和汉族人群ADRB2基因rs1042713和rs1042714位点的药物基因组学信息。方法:招募云南省临沧市佤族与汉族健康志愿者,进行ADRB2基因rs1042713和rs1042714位点基因型检测。基于Pharm GKB数据库选择亚洲人群,并分别与佤族和汉族人群进行等位基因频率比较。结果:研究对象的2个基因位点频率均符合Hardy-Weinberg遗传平衡。佤族与汉族人群ADRB2基因rs1042713和rs1042714位点的基因型频率和等位基因频率比较无统计学差异(P>0.05)。在亚洲具有代表性的人群中,其与越南人群rs1042713和rs1042714位点的等位基因频率比较无统计学差异(P>0.05);与日本人群rs1042713位点的等位基因频率存在统计学差异(P<0.05)。在我国具有代表性的人群中,其与北京汉族、南方汉族、西双版纳傣族人群rs1042713和rs1042714位点等位基因频率比较均无统计学差异(P>0.05)。结论:研究结果补充了云南佤族与汉族人群ADRB2基因rs1042713和rs1042714药物基因组学信息,为安全用药提供相关的理论基础。
Objective:To supplement and refine the pharmacogenomic information on the ADRB2 gene rs1042713 and rs1042714 loci in the Wa and Han populations.Methods:Healthy volunteers of Wa and Han ethnicity in Lincang City,Yunnan Province,were recruited for genotyping of the ADRB2 gene rs1042713 and rs1042714 loci.Asian populations were selected based on the PharmGKB database,and the allele frequencies were compared with those in Wa and Han populations,respectively.Results:The frequencies of the two loci in the study populations were in accordance with Hardy-Weinberg equilibrium.There were no statistically significant differences in genotype frequencies and allele frequencies of the ADRB2 gene rs1042713 and rs1042714 loci between the Wa and Han populations(P>0.05).In representative populations within Asia,the allele frequencies of the rs1042713 and rs1042714 loci showed no statistically significant differences compared to those in the Vietnamese population(P>0.05).However,significant differences were observed in the allele frequencies of the rs1042713 locus when compared to the Japanese population(P<0.05).In representative populations within China,the allele frequencies of the rs1042713 and rs1042714 loci showed no statistically significant differences compared to those in the Han population from Beijing,the Han population from southern China,and the Dai population from Xishuangbanna(P>0.05).Conclusion:The study results supplement the pharmacogenomic information on the ADRB2 gene rs1042713 and rs1042714 loci of the Wa and Han populations in Yunnan Province,providing a theoretical basis for safe medication.
作者
赵永艳
潘兴
李新蕊
杨春富
宋亮
李薇
ZHAO Yong-yan;PAN Xing;LI Xin-rui;YANG Chun-fu;SONG Liang;LI Wei(College of Pharmacy,Dali University,Dali 671000,China;Department of Science and Education,The People's Hospital of Lincang,Lincang 677000,China;Department of Respiratory and Critical Care Medicine,The People's Hospital of Lincang,Lincang 677000,China;Department of Clinical Pharmacy,The People's Hospital of Lincang,Lincang 677000,China)
出处
《中国合理用药探索》
2025年第3期16-22,共7页
Chinese Journal of Rational Drug Use
基金
云南省教育厅科学研究基金项目(2024J0865)
临沧市科技创新团队项目(202204AC100002-TD04)。
